Navigation Links
Verenium Announces $22.5 Million, Five-Year Secured Financing
Date:12/10/2012

ment team," said Richard Pines, a Partner of Athyrium. "We believe this transaction enables Verenium to continue to deploy its proven technology by creating highly differentiated enzyme products across a wide range of sectors and industrial applications."

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

About Athyrium Opportunities Fund

Athyrium Opportunities Fund is a New York-based fund focusing on investment opportunities in the global healthcare sector. The Athyrium investment team has substantial healthcare investment experience across a wide range of asset classes, including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across healthcare verticals, including biopharma, medical devices and products, and healthcare services. The team partners with management teams to implement creative financing solutions to companies' capital needs.

Forward Looking Statements For Verenium

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's ability to commercialize its products, enhance its manufacturing capabilities, capture near-term and longer-term growth and prospects, and reach profitability.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic fo
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported ... that supports the broad anti-viral potential of the ... its PS-targeting drug bavituximab can cure lethal virus ... Bavituximab is in clinical trials for the treatment ...
... ILE ) today announced that on March ... "Exchange") notifying the Company it is not in compliance ... "Company Guide"). Specifically, the Exchange staff noted that the ... to its overall operations or its existing financial sources ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for ... International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting ... to 22nd, 2009. The principal investigator for the trial ...
Cached Biology Technology:Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Isolagen, Inc. Receives Notification Letter from Amex 2Isolagen, Inc. Receives Notification Letter from Amex 3Isolagen, Inc. Receives Notification Letter from Amex 4Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 3
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... itself resulting in severe abdominal pain, vomiting and systemic ... are diagnosed with the disease resulting in 1000 deaths. ... to intravenous fluid and nutritional support. , Dr ... led the research, said "The major causes of pancreatitis ... alcohol intake combined with a high fat diet. In ...
(Date:8/20/2014)... CITY Researchers at Huntsman Cancer Institute (HCI) at the ... of the gene that encodes BCR-ABL, the unregulated enzyme ... to the American Cancer Society, nearly 6,000 new cases ... already in use, called tyrosine kinase inhibitors (TKIs), target ... do not cure CML but control it in a ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... symptom of physical pain or stress. But now a ... showing that tears have emotional benefits and can make ... Hasson of TAU,s Department of Zoology shows that tears ... an evolution-based mechanism to bring people closer together. ...
... by climate scientists at the University of East Anglia (UEA) ... field in the last two years. The article, ,Tipping ... Proceedings of the National Academy of Sciences in ... Paper, by Thomson Reuters. "The article captures the zeitgeist ...
... female cells counteract their double dose of X chromosomes by coating ... binds to the same X chromosome from which it is transcribed ... silencing. In the August 24, 2009 issue of the Journal ... the fact that XIST temporarily dissociates from the X chromosome during ...
Cached Biology News:Trust in a teardrop 2Tipping elements remain a 'hot' issue 2Tipping elements remain a 'hot' issue 3Aurora B answers an XIST-ential question 2
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
... enables you to identify over 150 ... distinguish protein isoforms, protein subsets, and ... visualize peptide-protein associations and relationships easily. ... identification and relative protein expression analysis ...
... The B1 series embodies all aspects of ... microscope. With powerful Achromatic Super Contrast (ASC) ... imaging chip, this microscope combines flexibility and ... Motic's popular B1 series, the DM-B1 steps ...
... a high-throuput screening of a biological systems ... induced changes in the expression levels of ... detected, studied, classified and compared to each ... at a glance. Automatized scanning of the ...
Biology Products: